Search

Displaying results 801 - 810 of 2160 in total
  1. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...

    Mixtures: Ultravate X, Ultravate X
  2. Drug

    Isoflurophate

    go.drugbank.com/drugs/DB00677
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)

  3. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.

  4. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regula...

  5. Drug

    Quinestrol

    go.drugbank.com/drugs/DB04575
    Approved

    The 3-cyclopentyl ether of ethinyl estradiol.

  6. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

    Mixtures: Clinimix E, Clinimix E
  7. Drug

    Cinchocaine

    go.drugbank.com/drugs/DB00527
    ApprovedVet approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)

  8. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  9. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  10. Drug

    VB10.16

    go.drugbank.com/drugs/DB17512
    Investigational

    It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting